About Docetaxel Injection IP Cetaxel RTU 80
Docetaxel Injection IP Cetaxel RTU 80 stands as an illustrious, top-tier oncology product, designed for unassailable efficacy in cancer therapy. Manufactured and marketed by Fresenius Kabi Oncology Ltd., this rare, ready-to-use (RTU) formulation streamlines clinical workflows with its pre-mixed presentation-eliminating the need for reconstitution. Each 4 ml single-use glass vial contains 80 mg Docetaxel, clearly marked with a barcode for traceability. Recommended for intravenous infusion, it is compatible with standard infusion solutions and shipped under strict cytotoxic safety protocols. Benefit from this Markdown promotion, available for authorized dealer, distributor, exporter, supplier, trader, wholesaler networks in India.
Versatile Usage & Applications of Docetaxel Injection IP Cetaxel RTU 80
Docetaxel Injection IP Cetaxel RTU 80 is specially formulated for intravenous (IV) administration and is indicated for treating breast, non-small cell lung, prostate, gastric, and head and neck cancers. Its application surface is thus strictly medical, targeting malignant cells intravenously. The RTU feature means healthcare professionals can immediately use it without extra dilution, saving valuable time. While not applicable to plant or industrial settings, its use in clinical environments helps improve patient care and treatment efficiency.
Certifications, Domestic & Export Markets for Cetaxel RTU 80
Cetaxel RTU 80 is regulated and approved by national drug authorities, confirming its distinguished status for patient safety. A competitive sale price and transparent charge structure make it accessible to the main domestic market of India and numerous key export markets. The product is shipped securely, aligned with cytotoxic handling guidelines, supporting dealers, distributors, exporters, suppliers, and wholesalers. Comprehensive certifications reinforce its reliability and value in both domestic and international marketplaces.
FAQ's of Docetaxel Injection IP Cetaxel RTU 80:
Q: How should Docetaxel Injection IP Cetaxel RTU 80 be administered for optimal efficacy?
A: Docetaxel Injection IP Cetaxel RTU 80 is administered via intravenous infusion by trained healthcare professionals, ensuring optimal delivery directly into the bloodstream for effective cancer treatment.
Q: What are the main benefits of choosing the RTU (Ready to Use) formulation of Cetaxel RTU 80?
A: The RTU formulation allows immediate use without further dilution, reducing preparation time, minimizing handling errors, and supporting safer, more efficient drug administration in clinical settings.
Q: When is Docetaxel Injection IP Cetaxel RTU 80 indicated for patient treatment?
A: Cetaxel RTU 80 is indicated for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric cancer, and head and neck cancers as prescribed by a qualified oncologist.
Q: What safety measures are required during the handling process?
A: As a cytotoxic drug, Cetaxel RTU 80 must be handled with appropriate protective gear and according to established cytotoxic drug handling protocols to safeguard healthcare workers and the environment.
Q: Where is Docetaxel Injection IP Cetaxel RTU 80 manufactured and distributed?
A: This product is marketed by Fresenius Kabi Oncology Ltd. in India and is available through licensed dealers, distributors, exporters, suppliers, traders, and wholesalers both domestically and internationally.